FDA Recalls Glutathione Injectable Due to Sterility Concerns
The Compounding Shop is recalling Glutathione 200 mg/mL Injectable vials because FDA inspections raised concerns about quality control and sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
The Compounding Shop, Inc. is recalling 7 vials of 50 mL each of Glutathione 200 mg/mL Injectable. The recall was initiated following FDA inspection findings that resulted in concerns regarding the quality control processes used to ensure the sterility of the product.
The affected product was distributed in Florida, California, Minnesota, and Maine. The recall covers all lots of this specific compounded injectable.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- Glutathione 200 mg/mL Injectable, 50 mL vials, compounded by The Compounding Shop, St. Petersburg, FL
- Manufacturer
- THE COMPOUNDING SHOP, INC.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 25 recalled by THE COMPOUNDING SHOP, INC. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 25 products in this recall →Related recalls
Same manufacturer · THE COMPOUNDING SHOP, INC.
See all →- SevereMitomycin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-06-12
- SevereTestosterone Cypionate Injectable Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereCompounded Injectable MIC Plus B12 Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereFDA Recalls Hydroxyprogesterone Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereMethotrexate Injectable Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereGlutathione Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- HighGlutathione Injectable Vials Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2022-07-20
- HighGlutathione Injectable Compounded Drug Recalled Due to Sterility Assurance Issues
FDA (Drugs) · 2022-07-20
- SevereFDA Recalls Injectable Glutathione Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereCustomceutical Compounding Recalls Glutathione Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2019-05-08
- SevereFDA Recalls Compounded Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17